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Interleukin (IL)-1β is a potential target for treatment of several inflammatory diseases, 
including envenomation by the scorpion Tityus serrulatus. In this context, bioactive lipids 
such as prostaglandin (PG)E2 and leukotriene (LT)B4 modulate the production of IL-1β 
by innate immune cells. Pattern recognition receptors (PRRs) that perceive T. serrulatus 
venom (TsV), and orchestrate LTB4, PGE2, and cyclic adenosine monophosphate (cAMP) 
production to regulate IL-1β release are unknown. Furthermore, molecular mechanisms 
driving human cell responses to TsV remain uncharacterized. Here, we identified that 
both CD14 and CD36 control the synthesis of bioactive lipids, inflammatory cytokines, 
and mortality mediated by TsV. CD14 induces PGE2/cAMP/IL-1β release and inflam-
mation. By contrast, CD36 shunts eicosanoid metabolism toward production of LTB4, 
which represses the PGE2/cAMP/IL-1β axis and mortality. Of importance, the molecular 
mechanisms observed in mice strongly correlate with those of human cell responses to 
TsV. Overall, this study provides major insights into molecular mechanisms connecting 
CD14 and CD36 with differential eicosanoid metabolism and inflammation mediated by 
IL-1β.
Keywords: interleukin-1β, leukotriene B4, prostaglandin e2, cyclic adenosine monophosphate, cD36 receptor, 
cD14 receptor, venom
inTrODUcTiOn
Inflammation is a critical process for the host response against pathogens and other harmful stimuli, 
such as toxins. However, fine-tuned regulatory mechanisms evolved to avoid adverse effects from 
excessive inflammation (1, 2). Innate immune cells, including macrophages, drive these responses 
by secreting a wide spectrum of soluble mediators (1, 3). Among them, bioactive lipids play critical 
roles to initiate and resolve inflammation (4). Activated innate immune cells produce and secrete 
eicosanoids, bioactive lipids derived from the ω-6 polyunsaturated fatty acid, arachidonic acid 
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(AA). Prostaglandin (PG) synthesis begins with AA oxygenation 
by cyclooxygenases 1 and 2 (COX1/2), while leukotrienes (LTs) 
derive from 5-lypoxygenase pathway activity (5-LO) (5). PGs 
and LTs mediate pleiotropic functions in inflammation, such as 
amplification or regulation of cytokine release (3, 6) and recruit-
ment of leukocytes (7–9). These events are triggered after pattern 
recognition receptors (PRRs) engage ligands of diverse chemical 
nature (1, 2, 10, 11). Toll-like receptors (TLRs) compose a well-
characterized family of PRRs, which recognize microbial prod-
ucts, endogenous signals of cellular damage, as well as toxins and 
venom compounds (2, 10–12). TLRs function cooperatively with 
each other or with several co-receptors, such as CD14 and CD36, 
to activate a variety of inflammatory signaling cascades (13–17).
Recently, we observed that mouse macrophages recognize 
Tityus serrulatus venom (TsV) through TLRs to mediate the 
production of inflammatory cytokines and bioactive lipids 
(11). Moreover, we demonstrated that TsV induces NLRP3 
inflammasome assembly, caspase-1 activation, and interleukin 
(IL)-1β maturation, which culminates in lung edema and death 
of envenomed mice (3). Inflammasome/caspase-1 activation 
and subsequent IL-1β release is potentiated by mechanisms 
that induce PGE2/cyclic adenosine monophosphate (cAMP) 
production, but repressed by LTB4 (3, 18, 19). In humans, several 
inflammatory cytokines are released in the circulation following 
a scorpion sting (20–22). While these studies revealed important 
immunopathological features of scorpion envenomation, PRRs 
that perceive effector TsV compounds, and induce bioactive 
eicosanoids to regulate IL-1β release remain unknown. In addi-
tion, it is still unclear whether the same mechanisms translate 
into inflammatory responses during scorpion envenomation in 
humans.
Both CD14 and CD36 display fundamental roles not only as 
co-receptors but also as major regulators of the inflammatory 
response (17). Their functions are dictated by TLR-dependent 
and -independent signaling cascades (23–25). CD14 is a glyco-
protein abundantly expressed in membranes of myeloid cells and 
commonly used as a monocyte/macrophage marker (26). Upon 
activation, monocytes secrete soluble form of CD14 (sCD14) 
(27), whereby several inflammatory conditions are associated 
with increased levels of circulating sCD14 (27–29). Widely stud-
ied due its role as a lipopolysaccharide (LPS) receptor, CD14 is 
also required for maximum production of tumor necrosis factor 
(TNF)-α, IL-6, and PGE2 by TsV-stimulated mouse macrophages 
(11). CD36 is expressed by multiple cell types and tissues, and 
binds to several pathogen and endogenous ligands (30, 31). 
Belonging to the class B scavenger receptor family, it has signifi-
cant roles in angiogenesis and control of fatty acid uptake (30). In 
addition, CD36 has emerged as a central molecule for inflamma-
some activation and consequent secretion of IL-1β during sterile 
inflammation (16).
Here, we show that CD14 induces a robust inflammatory 
response to TsV, controlling the production of PGE2, cAMP, and 
IL-1β by mouse macrophages in  vitro, while absence of CD14 
reduces lung inflammation and edema, increasing survival after 
envenomation in vivo. Strikingly, we identified a surprising role 
of CD36 on the regulation of TsV-induced IL-1β release. CD36 
specifically represses IL-1β secretion by driving eicosanoid 
metabolism toward LTB4 synthesis. Indeed, a CD36-deficient 
mouse strain (Cd36obl/obl) is highly susceptible to envenomation, 
while treatment with LTB4 rescues mice from fatal outcomes. 
Of importance, we confirmed that PGE2 levels are correlated 
with and boosts IL-1β production by human peripheral blood 
mononuclear cells (PBMCs) stimulated with TsV. However, dif-
ferential activity of enzymes involved in eicosanoid metabolism 
coordinates IL-1β levels.
MaTerials anD MeThODs
healthy human subjects and envenomed 
Patients
Peripheral blood (40  mL), peripheral blood mononuclear cells 
(PBMCs) and plasma samples were collected using tubes with 
heparin (BD Biosciences, San Diego, CA, USA) from healthy 
subjects of both sexes (n = 24) who had not taken anti-inflam-
matory drugs, had not used anticoagulant, or had not chronic 
inflammatory and infectious diseases (see Tables S1 and S2 in 
Supplementary Material). These procedures were approved by 
the School of Pharmaceutical Sciences of Ribeirão Preto Human 
Research Ethics Committee (protocol #54426115.1.0000.5403) 
and all subjects provided written informed consent.
Plasma samples were also collected from patients enven-
omed by T. serrulatus before treatment (n = 14, women to men 
ratio = 1.8, mean age ± SD = 5.6 ± 7.3 years). These procedures were 
approved by the Clinics Hospital of Ribeirão Preto Medical School 
Research Ethics Committee (protocol #54426115.1.3001.5440) 
and all patients provided written informed consent.
Whole Blood Flow cytometry analysis
Aliquots of fresh circulating blood (containing 1 × 106 leukocytes) 
were collected from 10 healthy subjects. Samples were incubated 
with vehicle or TsV for 4 h, and cell surface expression of CD14 and 
CD36 was determined by flow cytometry using fluorochrome-
conjugated antibodies (BD Biosciences, NJ, USA). Whole blood 
cells were stained with fluorescein isothiocyanate-conjugated 
anti-CD36 and allophycocyanin-conjugated anti-CD14 antibod-
ies. The cells were then washed with PBS containing 2% fetal 
bovine serum, pelleted by centrifugation at 400 ×  g and fixed 
with PBS containing 1% (w/V) paraformaldehyde. Data were 
acquired using a FACSCanto flow cytometer (Becton Dickinson, 
CA, USA) and analyzed with FlowJo software (Tree Star).
Peripheral Blood Mononuclear cells 
(PBMcs) isolation, TsV stimulation, and 
Pharmacological Treatments
PBMCs were isolated using Ficoll-Paque PLUS (GE Healthcare, 
Uppsala Sweden) density gradient centrifugation following the 
manufacturer’s instructions. PBMCs were plated at the density 
of 1 × 106 cells/well in 300 µL serum-free RPMI supplemented 
with antibiotics (incomplete RPMI-1640). The adhered cells were 
then cultured at 37°C (5% CO2) for 2 h. Next, the cells were pre-
incubated with or without indomethacin (30 min; 10 µM; Cayman 
Chemical, MI, USA), MK886 (30 min; 10 µM), PGE2 (10 min; 
10  µM; Cayman Chemical), LTB4 (10  min; 100  nM; Cayman 
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Chemical), or dexamethasone (1 h; 0.1 µM; Aché Laboratórios, 
São Paulo, Brazil). PGE2 and LTB4 from ethanol stock solution 
were suspended in serum-free RPMI, and an equivalent volume 
of ethanol (not more than 0.01%) was added to the RPMI; this 
solution was designated as the vehicle control. Indomethacin, 
MK886 (prediluted in PBS/0.01% ethanol), and dexamethasone 
were diluted in serum-free RPMI. RPMI containing the same 
proportion of ethanol was used to dilute the compounds, yielding 
the vehicle control. After treatment, PBMCs were stimulated with 
TsV (50 µg/mL) for 24 h at 37°C in a humidified atmosphere with 
5% CO2. Subsequently, the supernatants were collected for IL-1β 
quantification, and the cell lysate was used for analysis of gene 
expression.
Mice
This study was carried out in accordance with the institutional 
guidelines for ethics in animal experiments approved by the 
Animal Care Committee of the Campus of Ribeirão Preto 
(PCARP) at the University of São Paulo, Ribeirão Preto, Brazil 
(protocol #14.1.272.53.7). Six- to eight-week-old female or male 
mice were used for in vivo and in vitro experiments. The mice 
were matched by sex and age for all procedures. Cd14−/− (32), 
Tlr2−/− (33), and Tlr4−/− (34) mice were backcrossed with C57BL/6 
mice and were bred and maintained at the animal facilities of the 
Ribeirão Preto Medical School, University of São Paulo. Cd36obl/
Mmucd mice (15) were acquired from MMRRC (UC Davis) 
in heterozygosis and were inter-crossed to yield homozygotes 
mutants and wild-type mice; genotyping was performed by PCR 
followed by DNA sequencing as described (35). C57BL/6 (wild 
type) mice were obtained from the animal facilities of the PCARP, 
at the University of São Paulo, Ribeirão Preto, Brazil. Sample size 
was determined based on previous studies from our laboratory 
and literature and considering alpha and beta errors of 0.05 and 
0.20, respectively. We observed TsV-inoculated mice for 8  h. 
The time of death was used for survival analysis. The surviving 
mice were euthanized with an overdose of chemical anesthetics 
(100 mg/kg ketamine and 10 mg/kg xylazine) at 8 h after enveno-
mation or vehicle inoculation.
TsV, Ts1, and the Fatty acid-rich Fraction
Tityus serrulatus scorpions were maintained at the vivarium of 
the Ribeirão Preto Medical School, University of São Paulo, in 
accordance with the Brazilian Institute of Environment. TsV was 
obtained by electrical stimulation, and Ts1 toxin (representing 
16% of the total crude soluble TsV) was obtained as described 
previously (36). TsV and purified Ts1 were stored at −20°C until 
use. Prior to the experiments, TsV and Ts1 were diluted in PBS 
and filtered through a 0.22-µm sterilizing membrane (Millipore, 
Tullagreen, CO, USA). Limulus Amebocyte Lysate tests (QCL-
1000; Bio Whittaker, Cambrex Company, Walkersville, MD, 
USA) were performed to detect LPS in the TsV and Ts1 sam-
ples, according to the manufacturer’s instructions. No LPS was 
detected in TsV and Ts1 samples. To prepare the fatty acid-rich 
fraction, desiccated TsV (5 mg) was suspended in 200 µL cold 
ultrapure water (18.2 MΩ cm; Milli-Q water; Millipore, Bedford, 
MA, USA) and centrifuged at 12,400 × g and 4°C for 10 min. The 
supernatant was separated, and the precipitate was washed twice 
with 100 µL cold ultrapure water and centrifuged as described 
above. This precipitate containing mucus and fatty acids was 
designated the fatty acid-rich fraction, and the presence of lipids 
was confirmed by mass spectrometry.
activation of Mouse Peritoneal 
Macrophages by TsV and In Vitro 
Pharmacological Treatments
Resident peritoneal macrophages from naïve C57BL/6, Cd14−/−, 
Cd36obl/obl, Tlr2−/−, and Tlr4−/− mice were harvested by peritoneal 
washes with RPMI-1640 and were plated at a density of 2 × 105 
cells/well in 200 µL serum-free RPMI supplemented with anti-
biotics (incomplete RPMI-1640). The cells were then cultured at 
37°C (5% CO2) for 2 h. Next, the supernatants were removed, and 
the cells were pre-treated with or without Escherichia coli 01112.
B4 LPS (1,000 ng/mL; Sigma-Aldrich, St. Louis, MO, USA) for 
4 h. Next, PBS (vehicle), TsV, the fatty acid-rich fraction, or Ts1 
(50 µg/mL) in 200 µL incomplete RPMI was added, and the cells 
were incubated at 37°C in a humidified atmosphere containing 5% 
CO2. After 24 h, the supernatants were collected for IL-1β, PGE2, 
LTB4, IL-6, and TNFα quantification. In separate experiments, 
1 × 106 peritoneal macrophages/well in 48-well plates, collected 
from C57BL/6, Cd36obl/obl, and Cd14−/− mice, were incubated with 
incomplete RPMI medium following stimulation with or without 
TsV (50 µg/mL) for 4 or 24 h at 37°C in a humidified atmosphere 
containing 5% CO2 for analysis of mRNA expression by quanti-
tative real-time reverse transcription polymerase chain reaction 
(qRT-PCR). When indicated and before TsV stimulation, the 
cultured mouse peritoneal macrophages were pre-treated with 
forskolin (an adenylate cyclase agonist, 10 or 25  µM; 10  min; 
Sigma-Aldrich), MK886 (a FLAP inhibitor, 10  µM; 30  min), 
indomethacin (a COX1/2 inhibitor; 10  µM; 30  min, Cayman 
Chemical), H89 dihydrochloride hydrate [a protein kinase A 
(PKA) inhibitor, 25  µM, 2  h; Sigma-Aldrich], LTB4 (100  nM; 
10  min; Cayman Chemical), or U75302 (a BLT1 antagonist, 1 
or 10 µM; 30 min; Cayman Chemical). The same volume of the 
solvent used to suspend the compounds was added to RPMI (as 
the vehicle). Culture conditions, time, and concentration of each 
compound were based on our previous publication (3).
Quantitative real-Time reverse 
Transcription Polymerase chain reaction
RNA was extracted using a guanidine-based column method, 
according to the manufacturer’s protocol (Purelink, Ambion), 
and the quantity of RNA was determined by means of a fluoro-
metric assay (Qbit; Invitrogen, Carlsbad, CA, USA). cDNA was 
synthesized from 1 µg total RNA (High Quality cDNA Reverse 
Transcriptase Kits; Applied Biosystems, Foster City, CA, USA). 
Aliquots (2  µL) of total cDNA were amplified by qRT-PCR 
using TaqMan primers for human: PTGS2, CD14, CD36, TLR2, 
TLR4, ALOX5AP, ALOX-5, and CASP1 or mice: Alox5, Alox5ap, 
Cd14, Cd36, Casp1, Tlr2i, and Tlr4 in a StepOne Plus machine 
(Applied Biosystems). Gapdh and Actb were used as reference 
genes. Reactions were performed in duplicate, and amplification 
was performed under the following conditions: denaturation at 
95°C for 2 min, followed by 40 cycles of 95°C for 2 s and 60°C 
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for 20 s. The results were normalized to the expression levels of 
the endogenous internal controls Actb and Gapdh. The ΔΔCt 
method was used for the analysis.
In Vivo experiments and  
Pharmacological Treatments
In all experiments under all conditions, mice were weighed 
before experiments. Cd36obl/obl, Cd14−/−, and C57BL/6 mice 
without treatment were inoculated with a lethal dose of TsV or 
PBS (vehicle) (3). C57BL/6 or Cd36obl/obl mice were treated with 
or without 20 µL of LTB4 (Cayman Chemical—50 ng/mouse) via 
i.n. administration, or 20 µL of vehicle (PBS + 0.05% ethanol). 
LTB4 or vehicle was administered 2 and 0.5 h before the lethal 
dose of TsV (180 µg/kg). In an additional experiment, C57BL/6 
or Cd14−/− mice were treated with or without BLT1 antagonist 
(U75302, 50 ng/mouse, i.n.) in 20 µL vehicle (Cayman Chemical). 
BLT1 antagonist or vehicle (PBS + 0.05% ethanol) was admin-
istered 24, 12, and 2 h before inoculation with a lethal dose of 
TsV (180 µg/kg). Animals inoculated with 200 µL PBS (i.p.) were 
used as negative controls. Lungs were excised immediately after 
euthanasia (overdose of 20% ketamine plus 10% xylazine) 8  h 
after the injection of TsV or vehicle. Lungs were weighed, and 
200 mg of tissue was homogenized in 2 mL incomplete RPMI. 
After centrifugation (400 × g for 10 min), the supernatants were 
transferred to new tubes, split into two samples of 1 mL each, and 
stored at −80°C until use. For measurement of myeloperoxidase 
(MPO) activity, one lobule of a lung was cut, instantly frozen in 
liquid nitrogen, and stored at −80°C until use. Weighed lungs were 
used for the calculation of the lung/body weight index to evaluate 
lung edema. Samples of lung parenchyma were processed and 
stained with hematoxylin and eosin for histological analysis by 
blinded observers. Analysis of these sections was performed with 
a video camera (Leica Microsystems Ltd., Heebrugg, Switzerland) 
connected to a Leica microscope DMR (Leica, Microsystems 
GmbH, Wetzlar, Germany) attached to a computer. Images were 
processed by Leica QWin software (Leica Microsystems Image 
Solutions, Cambridge, UK).
Quantification of soluble  
Mediators and MPO
Interleukin-1β, IL-6, and TNF-α present in the supernatants of 
lung homogenates or cell cultures were quantified using enzyme-
linked immunosorbent assay (ELISA) kits (R&D Systems, 
Minneapolis, MN, USA). Lipids were purified from 1  mL of 
filtered supernatants from the lung homogenates using Sep-Pak 
C18 cartridges (Thermo Fisher Scientific, Bellefonte, PA, USA). 
Measurements of LTB4 and PGE2 concentrations of lungs or cell 
cultures were performed by enzyme immunoassays (Enzo Life 
Sciences, NY, USA). Supernatants of the lung homogenates were 
used for measurement of MPO activity as described previously 
(37). Total protein was quantified using Coomassie Protein Assay 
Reagent (Pierce Chemical, Rockford, IL, USA). Levels of human 
soluble CD14 (sCD14) were determined by Quantikine Human 
sCD14 Immunoassay (R&D Systems Inc., Minneapolis, MN, 
USA). Levels of PGE2 secreted by human PBMCs were measured 
by LC-MS/MS as described previously (38, 39).
Quantification of intracellular caMP
For intracellular cAMP measurement, peritoneal macrophages 
were harvested from naïve C57BL/6, Cd36obl/obl, or Cd14−/− mice, 
and 1 × 106 cells/well were seeded in 48-well plates. The plates 
were then incubated with 1 mL serum-free RPMI with or without 
TsV (50 µg/mL) for 5 min at 37°C in 5% CO2. Culture superna-
tants were aspirated, and the cells were lysed by incubation for 
10 min with 0.1 M HCl at room temperature, followed by disrup-
tion using a cell scraper (3). Intracellular cAMP was quantified 
by ELISA, according to the manufacturer’s acetylation protocol 
(Enzo Life Sciences, Farmingdale, NY, USA).
statistical analyses
For comparison of multiple groups of animals, we performed 
one-way analysis of variance (ANOVA) or Kruskal–Wallis tests, 
followed by Bonferroni’s or Dunn’s multiple comparison tests, 
respectively. Differences between two groups were evaluated using 
paired or unpaired two-tailed Student’s t-tests. Shapiro–Wilk 
normality test was used to evaluate data distribution and gene 
expression was evaluated using one-sample t-test or Wilcoxon 
signed rank test. Differences in survival were analyzed using log-
rank tests. Pearson’s correlation was used to identify significant 
associations. All calculations were performed in GraphPad Prism 
5.0 software (GraphPad, San Diego, CA, USA). Differences with 
P values of less than 0.05 were considered statistically significant.
The frequency of high cytokine producers was calculated as 
previously proposed by Luiza-Silva et al. (40). Briefly, the global 
median cytokine frequency was calculated for each PBMC sub-
population using the entire data universe (n = 24 subjects), each 
subject was categorized as a “low” (below the global median) or 
“high” (higher than or equal to the global median) responder.
resUlTs
Opposing roles of cD14 or cD36 on the 
induction of il-1β by TsV-stimulated 
Mouse Macrophages
In response to TsV, C57BL/6 (wild type) mouse macrophages 
increase IL-1β secretion via PGE2–cAMP–PKA–NFκB pathway 
and activation of NLRP3 inflammasome, a molecular mechanism 
that is repressed by LTB4 (3). We have previously demonstrated 
that CD14 induces inflammatory cytokines and PGE2 produc-
tion in response to TsV (11), whereas CD36 has been implicated 
on inflammasome activation and IL-1β maturation (16). We 
thus postulated that CD14 and CD36 could be involved in TsV 
sensing and positive regulation of IL-1β production. In line with 
these observations, TsV-stimulated peritoneal macrophages 
from C57BL/6 mice upregulated Cd14 and Cd36 gene expression 
(see Figure S1A in Supplementary Material) (11). To determine 
whether CD14 and CD36 directly affect TsV-induced IL-1β 
release, we quantified IL-1β secreted by peritoneal macrophages, 
from C57BL/6, Cd14−/−, and Cd36obl/obl mice, stimulated with 
TsV or LPS; or treated with LPS and further incubated with TsV. 
Compared to wild-type cells, those from Cd14−/− mice failed to 
produce significant amounts of IL-1β, whose levels were compa-
rable to those of cells stimulated with LPS or with both stimuli 
FigUre 1 | Differential regulation of interleukin (IL)-1β promoted by CD14 and CD36 is independent of Tityus serrulatus venom (TsV) lipids. (a,B) IL-1β was 
determined in supernatants of C57BL/6 (WT), Cd14−/−, or Cd36obl/obl cells pre-treated with or without lipopolysaccharide (LPS) (1,000 ng/mL for 4 h), followed by 
incubation with RPMI-I (vehicle) or TsV (50 µg/mL for 20 h). (c,D) C57BL/6 (WT), Cd14−/−, or Cd36obl/obl cells were incubated with crude TsV, the fatty acid-enriched 
fraction, or Ts1 toxin (50 µg/mL for 24 h) for IL-1β measurements. Cells from each mouse strain incubated with vehicle (medium) were used as controls [continuous 
lines (C57BL/6) or dashed lines (Cd14−/− or Cd36obl/obl)]. Data are representative of two experiments (n = 4 in each experiment). Differences with P values of less than 
0.05 were considered significant according to one-way analysis of variance with Bonferroni’s post hoc test, and error bars denote SDs. *Vehicle versus stimuli; 
$C57BL6 versus Cd36obl/obl or Cd14−/−; #TsV versus other stimuli.
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(Figure  1A). Surprisingly, Cd36obl/obl macrophages stimulated 
with TsV or LPS released higher levels of IL-1β compared to wild-
type cells (Figure 1B). Moreover, Cd36obl/obl cells incubated with 
both stimuli released similar amounts of IL-1β induced by TsV 
or LPS alone, suggesting that levels of secreted IL-1β reached a 
maximum under all conditions (ceiling effect). To confirm that the 
opposing roles of CD14 and CD36 were confined to the release of 
IL-1β, we quantified TNF-α and IL-6 secreted by TsV-stimulated 
macrophages. We found that both Cd14−/− and Cd36obl/obl cells 
secreted less TNF-α and IL-6 than wild-type cells (see Figure S1B 
in Supplementary Material). These data show that both CD14 
and CD36 induce pro-inflammatory cytokine response upon 
TsV stimulation. However, CD36 was also required to specifically 
repress IL-1β secretion by mouse macrophages.
CD36 functions as a scavenger receptor known to bind to 
fatty acids, while CD14 has also been shown to interact with this 
subclass of lipids (30, 41). TsV is composed by a plethora of mol-
ecules, that can be separated into a fatty acid-enriched fraction 
(rich in lipids and carbohydrates), or purified toxins, whereby 
Ts1 is the major TsV effector protein (42, 43). To understand 
the chemical nature of TsV effectors activating both receptors, 
we stimulated C57BL/6-, Cd14−/−-, and Cd36obl/obl-peritoneal 
macrophages with crude TsV, the fatty acid-enriched fraction, or 
purified Ts1. Compared to vehicle-stimulated wild-type cells, all 
stimuli induced IL-1β production, although crude TsV was more 
potent than the two isolated fractions (Figures 1C,D). Of note, 
neither TsV nor any of the isolated fractions induced higher IL-1β 
release by CD14-deficient cells (Figure 1C). TsV and Ts1 induced 
significant IL-1β release by Cd36obl/obl macrophages, whereas the 
fatty acid-enriched fraction induced similar levels to that of 
wild-type cells (Figure 1D). Previous work has shown that both 
receptors can be activated by proteins or lipoproteins (44, 45), 
whereas these findings indicate that Ts1 is the main TsV effector 
toxin inducing IL-1β secretion by mouse macrophages.
il-1β, caMP, lTB4, and Pge2 are 
Differentially regulated by cD14 and cD36 
in TsV-stimulated Mouse Macrophages
Given the importance of PRRs and eicosanoid metabolism on 
the induction of pro-inflammatory cytokines in response to 
TsV, we stimulated peritoneal macrophages from Cd14−/− and 
Cd36obl/obl mice with TsV, and evaluated the relative gene expres-
sion of Cd14, Cd36, Tlr2, Tlr4, Pges2, Aloxap, Alox-5, and Casp1. 
Of interest, Cd36, Tlr4, and Alox5 expression was significantly 
upregulated in TsV-stimulated Cd14−/− peritoneal macrophages, 
whereas Tlr2 and Casp1 were significantly downregulated 
compared to vehicle-treated cells (Figure  2A). By contrast, 
TsV-stimulated macrophages from Cd36obl/obl mouse exhibited 
significant increase on the expression of Cd14, Tlr2, Tlr4, Pges2, 
and Casp1, while Alox5 and Alox5ap were downregulated com-
pared to vehicle-treated cells (Figure 2B). These data suggest that 
FigUre 2 | CD14 and CD36 promote differential eicosanoid metabolism to control interleukin (IL)-1β release by macrophages. (a,B) Peritoneal macrophages from 
Cd14−/− or Cd36obl/obl mice were stimulated or not with Tityus serrulatus venom (TsV) (50 µg/mL) for 24 h and used to determine gene expression profiles by 
quantitative real-time reverse transcription polymerase chain reaction. The results were normalized to the expression of the endogenous internal control Gapdh. The 
ΔΔCt method was used for the analysis, and the data were expressed as log2 fold-change in relation to the control (vehicle) from two independent experiments 
(n = 3 in each experiment). *Vehicle versus TsV, by two-tailed Student’s t-test, with P < 0.05. (c,D) Peritoneal macrophages of C57BL/6, Cd14−/−, or Cd36obl/obl mice 
were stimulated with TsV (50 µg/mL) for 24 h, and supernatants were collected for IL-1β, leukotriene (LT)B4, prostaglandin (PG)E2, tumor necrosis factor (TNF)-α, and 
IL-6 quantification by enzyme-linked immunosorbent assay. In a separate set of experiments, cyclic adenosine monophosphate production was quantified at 5 min 
after TsV (50 µg/mL) stimulation. In all experiments, cells incubated with medium (vehicle) were used as controls. Data are representative of three independent 
experiments (n = 4 in each experiment). Significant differences are marked with symbols, and error bars denote SDs. *Vehicle versus TsV; #C57BL/6 (WT) versus 
Cd36obl/obl or Cd14−/−. P < 0.05 according to one-way analysis of variance (ANOVA) with Bonferroni’s post hoc test. (e) Peritoneal macrophages from C57BL/6 or 
Cd14−/− mice were pre-treated as indicated with U75302 (BLT1 antagonist, 30 min) or forskolin (Forsk, 10 min) before addition of TsV (50 µg/mL) for 24 h. (F) 
Peritoneal macrophages from C57BL/6 or Cd36obl/obl mice were pre-treated with or without H89 (25 µM, 2 h), soluble LTB4 (100 nM, 10 min), or indomethacin (Indo, 
10 µM, 30 min). Supernatants were collected for IL-1β quantification. In all experiments, cells in medium containing the vehicle were used as controls (Vehicle). Data 
are representative of two independent experiments (n = 4 in each experiment). Significant differences (P < 0.05) are marked with symbols, and error bars denote 
SDs. *Vehicle versus TsV; #TsV versus treatment; $C57BL/6 versus Cd36obl/obl or Cd14−/−, according to one-way ANOVA with Bonferroni’s post hoc test.
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after TsV engagement, CD14 and CD36 regulate each other at the 
transcriptional level. Importantly, the results indicate that CD14 
and CD36 may affect IL-1β release by inducing PGE2 or LTB4 
production, respectively.
We tested this hypothesis by stimulating Cd14−/−, Cd36obl/obl, 
and wild-type peritoneal macrophages with TsV to evaluate the 
release of IL-1β, LTB4, PGE2, and cAMP synthesis. Compared 
to wild-type cells, TsV-stimulated peritoneal macrophages from 
Cd14−/− mouse produced 92% less IL-1β, 97% less cAMP and 
96% less PGE2, but 30% more LTB4 (Figure 2C). Of note, mac-
rophages from Cd36obl/obl mouse incubated with vehicle produced 
significantly higher amounts of cAMP and PGE2 (Figure  2D). 
Moreover, TsV-stimulated peritoneal macrophages from Cd36obl/
obl increased IL-1β production by 49%, cAMP by 123%, and PGE2 
by 15%, while LTB4 production decreased by 99% (Figure 2D). 
We validated these findings using pharmacological assays. First, 
peritoneal macrophages from Cd14−/− mice were stimulated 
with TsV after pre-treatment with increasing concentrations of 
a BLT1 antagonist (to block signaling by LTB4), or forskolin (an 
adenylate cyclase activator, which increases cAMP levels) (3). 
As expected, low concentrations of BLT1 antagonist (1 µM) or 
forskolin (10 µM) already increased IL-1β production by wild-
type cells; however, only treatment with higher concentrations of 
BLT1 antagonist (10 µM) and forskolin (25 µM) potentiated IL-1β 
production by macrophages from Cd14−/− mouse (Figure  2E). 
In addition, peritoneal macrophages from Cd36obl/obl mouse were 
stimulated with TsV after pre-treatment with the compound 
H89, a PKA inhibitor, LTB4, and indomethacin (COX1/2 inhibi-
tor). IL-1β production by peritoneal macrophages from C56BL/6 
and Cd36obl/obl was inhibited by all compounds, but with distinct 
levels of magnitude (Figure  2F). Taken together, these data 
indicate that CD14 promotes PGE2, cAMP, and IL-1β release by 
peritoneal macrophages upon TsV challenge. By contrast, CD36 
is critical for 5-LO pathway activation and downregulation of 
IL-1β release.
Both CD14 and CD36 play major roles as TLR co-receptors, 
and recruit TLR-dependent and independent signaling path-
ways (17). Moreover, the absence of CD14 or CD36 promotes 
differential gene expression of Tlr2 and Tlr4 in TsV-stimulated 
peritoneal macrophages (Figures 2A,B). To understand whether 
TLRs are required for responses conferred by TsV-activation of 
CD14 and CD36, we stimulated peritoneal macrophages from 
Tlr2−/− or Tlr4−/− mice with TsV. We measured IL-1β, PGE2, TNF-
α, and IL-6 production, and Ptgs2 gene expression. Compared to 
wild-type cells, TsV-stimulated Tlr2−/− cells showed higher PGE2 
production (see Figure S2A in Supplementary Material) (11) and 
Ptgs2 expression (see Figure S2B in Supplementary Material). 
However, they released less IL-1β, TNF-α, and IL-6 (see Figures 
S2C–E in Supplementary Material) (11). This indicates that, in 
response to TsV, TLR2 partially control the IL-1β production 
and release by distinct mechanisms. By contrast, TsV-stimulated 
Tlr4−/− macrophages released significantly less PGE2, IL-1β, 
TNF-α, and IL-6 and expressed less Ptgs2 (see Figure S2 in 
Supplementary Material) (11). These results show that TLR4 
is also required for PGE2 and IL-1β release in response to TsV, 
suggesting that CD14 may mediate its effects through a TLR4-
dependent signaling pathway. Importantly, these results suggest 
that CD36 controls a regulatory mechanism that is independent 
of TLR2/4 signaling.
cD14-Deficient Mice are resistant to TsV, 
While lTB4 antagonist Potentiates 
inflammation and Mortality
Envenomation with TsV culminates in lung inflammation and 
edema, resultant from the inflammatory effects of IL-1β (3). In 
line with these observations, and based on the results obtained 
in  vitro, we investigated whether CD14 contributes to TsV-
induced lung inflammation and mortality in  vivo. Wild-type 
and Cd14−/− mice were weighed and inoculated intraperitoneally 
(i.p.) with a lethal dose of TsV (180 µg/kg), and mortality was 
observed for 8  h (Figure  3A). An additional group of lethally 
envenomed mice from both strains was treated with BLT1 
antagonist U75302. After envenomation, 100% of CD14-deficient 
animals survived, in contrast to 67% of wild-type animals 
(Figure 3A). We assessed lung tissues after animal death and cal-
culated the lung index, which reflects lung edema. Interestingly, 
TsV-inoculated Cd14−/− mice exhibited reduced lung edema 
compared to C57BL/6 mice (Figure  3B). Moreover, lungs of 
TsV-inoculated Cd14−/− mice exhibited reduced levels of IL-1β 
(Figure 3C) and PGE2 (Figure 3D); but showed similar amounts 
of protein in the parenchyma (Figure  3E) and released higher 
levels of LTB4 (Figure 3F). Unexpectedly, the lungs of vehicle-
inoculated Cd14−/− mice showed abundant neutrophils compared 
to wild-type mice, as demonstrated by MPO quantification 
(Figure 3G). However, the cellular content was not affected after 
TsV inoculation (Figure  3G). These findings were confirmed 
by histological analysis of the lungs (Figure 3H). As predicted, 
treatment of envenomed mice with the BLT1 antagonist U75302 
worsened inflammation, regardless the mouse strain; 100% of 
mice from both strains died within 4  h (Figure  3A), released 
higher amounts of IL-1β and PGE2 in the lung (Figures 3C,D), 
and developed stronger edema (Figures  3B,E). These findings 
support our previous observations that in this context, LTB4 
binding to BLT1 exhibits a regulatory activity (3). Overall, these 
results demonstrate that CD14 is an inflammatory receptor that 
contributes to lung inflammation and mortality induced by TsV 
via PGE2–cAMP–IL-1β release.
cD36-Deficient Mice are susceptible to 
TsV, and lTB4 Treatment rescues Fatal 
Outcomes
In response to TsV, CD36-deficient mouse macrophages sig-
nificantly increase IL-1β secretion, suggesting that upon scor-
pion envenomation, these animals might develop exacerbated 
inflammatory responses. Indeed, Cd36obl/obl mice were highly 
susceptible to TsV compared to wild-type mice; 83% of deficient 
mice died in the first 2 h, in contrast to only 67% of C57BL/6 
mice within 8 h (Figure 4A). Interestingly, exogenous adminis-
tration of LTB4 abrogated TsV-induced mortality in both mice 
strains (Figure 4A). Cd36obl/obl mice exhibited robust lung edema, 
measured by lung weight and index (Figure  4B). Consistent 
with the augmented sensitivity of CD36-deficient mice to TsV, 
the concentrations of IL-1β (Figure 4C), PGE2 (Figure 4D), and 
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FigUre 3 | Continued
FigUre 3 | CD14 mediates Tityus serrulatus venom (TsV)-induced lung inflammation and mortality, which are potentiated by BLT1 antagonism. C57BL/6 (WT)  
mice and Cd14−/− mice treated with the BLT1 antagonist (U-75302, 50 ng/mouse, i.n.) or vehicle were inoculated with a lethal dose of TsV (180 µg/kg, i.p.). Mice 
inoculated with PBS were used as controls. (a) Survival was monitored for 8 h. The experiment was conducted once using six mice, and error bars denote SDs. 
Differences with P values of less than 0.05 were considered significant (log-rank tests). All mice were weighed immediately before injection, and the lungs were 
excised instantly after animal death or from mice surviving for 8 h and weighed. (B) Lung indexes were calculated by determining the ratio of lung weight to  
body weight multiplied by 100. Lungs were then employed for analysis of (c) interleukin (IL)-1β, (D) prostaglandin (PG)E2, (e) total protein, (F) leukotriene (LT)B4 
concentrations, and (g) myeloperoxidase (MPO) activity. The experiment was conducted once using six mice per group, and error bars denote SDs. *PBS versus 
vehicle plus TsV or BLT1 antagonist plus TsV; #vehicle plus TsV versus BLT1 antagonist plus TsV; $C57BL/6 mice versus Cd14−/− mice. Differences with P values  
of less than 0.05 were considered significant according to one-way analysis of variance with Bonferroni’s post hoc test. (h) Lungs were prepared for staining  
with hematoxylin and eosin (H&E) for histological analysis (n = 4). Histopathology of lung tissues was examined [100× and 1,000× (inset) magnification].
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total protein (Figure 4E) were significantly higher, whereas that 
of LTB4 (Figure 4F) was significantly lower compared to C57BL/6 
animals. Interestingly, Cd36obl/obl vehicle-inoculated animals 
showed increased numbers of neutrophils (Figures 4G,H). TsV 
inoculation induced recruitment of these granulocytes into the 
lung, whereas a robust increase in MPO was observed in C57BL/6 
animals (Figure 4G). These results were confirmed by lung his-
tology (Figure 4H), showing that CD36 deficiency resulted in a 
pro-inflammatory phenotype and that leukocytes accumulated 
in the parenchyma. As predicted, administration of exogenous 
LTB4 inhibited IL-1β, PGE2, protein extravasation, and edema 
in both strains of mice (Figures 4B–E), corroborating the anti-
inflammatory activity of this 5-LO catabolite. These data confirm 
the regulatory role of CD36 receptor, protecting the host from 
excessive inflammation and mortality.
il-1β release by TsV-stimulated human 
PBMcs is controlled by lTB4 and Pge2 
Balance
Together with our previous observations (3), data presented here 
provide compelling evidences for molecular mechanisms control-
ling TsV-induced inflammatory responses and mortality in mice. 
However, the mechanisms that drive inflammatory cascades and 
IL-1β release by human cells during scorpion envenomation 
have not been investigated. Notably, envenomed patients exhibit 
high levels of systemic sCD14 compared to healthy controls 
(see Figure S3A in Supplementary Material), indicating that 
monocytes are robustly activated after scorpion sting (27). TsV 
stimulation of whole blood, from a subset of 10 healthy subjects, 
revealed decreased cell membrane expression of CD14 measured 
by flow cytometry (see Figure S3B in Supplementary Material), 
while CD36 expression remained unaltered (see Figure S3C in 
Supplementary Material). We obtained further insights by isolat-
ing PBMCs from 24 healthy subjects, which were later incubated 
with TsV. PBMCs stimulated with TsV increased gene expres-
sion of CD36, CD14, PTGS1, PTGS2, ALOX5, and ALOXAP 
compared to vehicle-stimulated cells (Figure  5A). Moreover, 
we identified a significant positive correlation between levels 
of PGE2 and IL-1β secreted by TsV-stimulated human PBMCs 
(Figure  5B). We then proceeded by pre-treating the cells with 
vehicle, PGE2, LTB4, the COX1/2 inhibitor indomethacin, or the 
5-lipoxygenase-activating protein (FLAP) inhibitor MK886; fol-
lowed by stimulation with TsV for 24 h and IL-1β quantification. 
Compared to vehicle-treated PBMCs, TsV induced significant 
IL-1β release (range: 13–298  pg/mL) (Figure  5C). Compared 
to TsV-stimulated PBMCs, pre-treatment with PGE2 increased 
IL-1β release significantly, while indomethacin and dexametha-
sone significantly decreased IL-1β release (Figure 5C). After TsV 
stimulation, PBMCs also released increased amounts of IL-6, 
whereas only 50% of volunteers showed increased TNF-α when 
compared with cells incubated with vehicle (see Figures S3D,E in 
Supplementary Material).
We observed highly variable levels of IL-1β released by 
human PBMCs. We thus hypothesized that a differential activity 
of enzymes involved in the metabolism of LTB4 and PGE2 could 
explain these variations. Therefore, using the median IL-1β 
concentration value (42  pg/mL of IL-1β per 5 ×  105 PBMCs), 
we classified volunteers into low or high responders based on 
their ability to release IL-1β upon TsV stimulation. As expected, 
PBMCs from high responders secreted increased amounts of 
IL-1β and PGE2 (see Figures S3F,G in Supplementary Material). 
Furthermore, the significance in expression of CD36, CD14, 
PTGS1, PTGS2, ALOX5, and ALOXAP changed according to 
the group of subjects relative to vehicle-stimulated PBMCs. 
Low responders only exhibited significant increase in expres-
sion of ALOXAP (Figure 6A), while high responders exhibited 
significant increase in expression of both PTGS2 and ALOXAP 
(Figure 6B). We were unable to identify significant differences 
in gene expression between low and high responders by compar-
ing difference between expression of single genes. However, we 
identified significant difference between low and high responders 
on the interaction term of CD14*CD36 (F1.22 = 4.61, P = 0.043) 
(Figure 6C). This suggests that after stimulation with TsV, there 
is a significant association between gene expression of CD14 and 
CD36, which correlates with the magnitude of IL1-β release. 
Irrespective of classification group, gene expression was not 
significantly correlated with IL1-β quantification, possibly due 
differential dynamics on transcription and translation after 
TsV stimulation. However, correlation networks based on the 
expression of the studied genes demonstrate different association 
patterns between low and high responders (see Figure S3H in 
Supplementary Material). For example, high responders exhib-
ited weaker correlations of CD36 with ALOXAP and PTGS2 
compared to low responders (see Figure S3H in Supplementary 
Material).
Both groups (high and low responders) exhibited significant 
increase in IL-1β release compared to vehicle-stimulated PBMCs 
(Figure 6D). Compared to TsV-stimulated PBMCs, pre-treatment 
with PGE2 induced significant increase in IL-1β release, while dex-
amethasone decreased IL-1β release in both groups (Figure 6D). 
Pre-treatment with LTB4 or indomethacin significantly reduced 
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FigUre 4 | Continued
FigUre 5 | Prostaglandin (PG)E2 boosts Tityus serrulatus venom (TsV) induced interleukin (IL)-1β release by human peripheral blood mononuclear cells (PBMCs). 
(a) PBMCs from healthy individuals were stimulated with or without TsV (50 µg/mL) for 24 h, and the cell lysates were collected for gene expression analyses of 
CD36, CD14, PTGS1, PTGS2, ALOX5, and ALOX5AP by quantitative real-time reverse transcription polymerase chain reaction (n = 24). (B) Culture supernatants 
were used for IL-1β quantification by enzyme-linked immunosorbent assay or PGE2 by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Correlation 
analysis was performed with Spearman’s correlation method (n = 24). (c) PBMCs from healthy individuals were pre-treated with or without PGE2 (10 µM, 10 min, 
n = 24), leukotriene (LT)B4 (100 nM, 10 min, n = 24), indomethacin (Indo, 10 µM, 30 min, n = 24), MK886 (10 µM, 30 min, n = 22), or dexamethasone (Dexa, 
0.1 µM, 1 h, n = 12) before addition of TsV (50 µg/mL) for 24 h. In all experiments, unstimulated (vehicle) cells were used as controls. Paired two-tailed Student’s 
t-test was used to evaluate differences. Significance is given as *P < 0.05, **P < 0.01, and ***P < 0.001.
FigUre 4 | CD36 controls a regulatory mechanism that depends on leukotriene (LT)B4 production. C57BL/6 (WT) and Cd36obl/obl mice treated with exogenous LTB4 
(50 ng/mouse, i.n.) or vehicle were inoculated with a lethal dose of Tityus serrulatus venom (TsV) (180 µg/kg, i.p.). Mice inoculated with PBS were used as controls. 
(a) Survival was monitored for 8 h. The experiment was conducted once using six mice, and the error bars denote SDs. The differences were considered significant 
when the P value was less than 0.05 according to log-rank tests. All mice were weighed immediately before the injections, and the lungs were excised instantly after 
animal death or from mice surviving until 8 h and weighed. (B) Lung indexes were calculated by determining the ratio of lung weight to body weight multiplied by 
100. Lungs were then employed for analysis of (c) interleukin (IL)-1β, (D) prostaglandin (PG)E2, (e) total protein, (F) LTB4 concentrations, and (g) myeloperoxidase 
(MPO) activity. The experiment was conducted once with six mice per group, and error bars denote SDs. *PBS versus vehicle plus TsV or LTB4 plus TsV; #vehicle 
plus TsV versus LTB4 plus TsV; $C57BL/6 mice versus Cd36obl/obl mice. These differences were considered significant when the P value was less than 0.05 according 
to one-way analysis of variance with Bonferroni’s post hoc test. (h) Lungs were prepared for staining with hematoxylin and eosin (H&E) for histological analysis 
(n = 4). The histopathology of lung tissues was examined [100× and 1,000× (inset) magnification].
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IL-1β release by high responders (Figure 6D). However, treatment 
with the MK886 significantly increased IL-1β release only in low 
responders (Figure 6D). These results support a mechanism in 
which PGE2 boosts IL-1β production and release in response to 
TsV, while levels of IL-1β are determined by differential activity of 
eicosanoid metabolism in low and high responders.
DiscUssiOn
In this study, we demonstrated the pivotal, but contrasting roles 
of CD14 and CD36 receptors in the regulation of LTB4, PGE2, and 
cAMP production, and control of IL-1β-mediated inflammation. 
Moreover, we confirmed that human cell responses to TsV are 
FigUre 6 | Differential eicosanoid metabolism determines the levels of interleukin (IL)-1β released by Tityus serrulatus venom (TsV)-stimulated human PBMCs. 
Individuals were classified into low (n = 12) or high (n = 12) responders based on the median value IL-1β upon stimulation with or without TsV (50 µg/mL) for 24 h. 
(a,B) Cell lysates were collected for gene expression analyses of CD36, CD14, PTGS1, PTGS2, ALOX5, and ALOX5AP by quantitative real-time reverse 
transcription polymerase chain reaction. (c) Two-way analysis of variance of gene expression of CD36 and CD14 between low and high responders. (D) PBMCs 
from low or high responders were pre-treated with or without prostaglandin (PG)E2 (10 µM, 10 min, n = 24), leukotriene (LT)B4 (100 nM, 10 min, n = 24), 
indomethacin (Indo, 10 µM, 30 min, n = 24), MK886 (10 µM, 30 min, n = 22), or dexamethasone (Dexa, 0.1 µM, 1 h, n = 12) before addition of TsV (50 µg/mL) for 
24 h. In all experiments, unstimulated (vehicle) cells were used as controls. Paired two-tailed Student’s t-test was used to evaluate differences. Significance is given 
as *P < 0.05, **P < 0.01, and ***P < 0.001.
12
Zoccal et al. CD36 Represses CD14 Licensed IL-1β
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 890
driven by mechanisms compatible with those observed in mice. 
These findings are particularly relevant in translational medicine. 
Scorpion envenomed patients exhibit clinical manifestations 
varying from local lesions to severe lung inflammation and car-
diogenic shock, which can be fatal (20–22, 43, 46). TsV induces 
substantial release of inflammatory cytokines. However, the 
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balance between 5-LO and COX1/2 catabolites control the levels 
of inflammasome-derived IL-1β, a potential determinant of 
human envenomation severity, as observed in mice (3). We con-
firmed that human PBMCs responded to TsV by releasing IL-1β, 
although levels of IL-1β production varied greatly. In almost all 
PBMCs, PGE2 increased IL-1β release, with substantial variations 
in the LTB4 response. However, when donors were classified into 
low and high cytokine responders, we found that high IL-1β 
responders were more sensitive to indomethacin and LTB4 than 
low responders, and low IL-1β responders were more responsive 
to MK886 than high responders. Thus, although PGE2 boosts 
IL-1β production in human cells, levels of this cytokine seem to 
be determined by the differential activity of enzymes involved 
in eicosanoid metabolism. To the best of our knowledge, these 
findings are the first to provide mechanistic insights into human 
responses to scorpion envenomation.
CD14 activation by LPS induces microsomal PGE synthase-1, 
PGE2 production, and skin edema formation via a mechanism that 
is independent of TLR signaling, but dependent on the transcrip-
tional activator nuclear factor of activated T cells (24). However, 
our data suggest that CD14 induces PGE2 and IL-1β release by a 
pathway that is at least partially dependent on TLR4 signaling. 
PGE2 signals through interaction with four G protein-coupled 
receptors, EP1-EP4. While EP2 and EP4 activation by PGE2 pro-
motes suppressive effects via cAMP/PKA/CREB pathway (47), 
TsV induces a different molecular signaling pathway that culmi-
nates with pro-inflammatory cytokine production via cAMP/
PKA/NF-κB (3, 11). Interestingly, PGE2 induces CD14 expression 
in macrophages via cAMP/PKA (48), suggesting a regulatory 
loop between cAMP and CD14, and control over IL-1β-mediated 
inflammation. Cd14−/− derived peritoneal macrophages produce 
more LTB4 than wild-type cells when stimulated with TsV (11), 
while the effects of U75302, a BLT1 antagonist, or forskolin (a 
PKA activator), were only observed using higher concentrations 
of these compounds. This suggests that Cd14−/− cells expressed 
less BLT1 and/or more BLT2 receptors. The expression of BLT1 
is higher in CD14+ monocytes (49). In the lungs, TsV-inoculated 
CD14-deficient mice also released significantly more LTB4 than 
C57BL/6 mice, and the concentrations of IL-1β and PGE2 were 
close to zero. Moreover, higher amounts of LTB4 in Cd14−/− 
animals protected the mice from TsV-induced lung edema and 
death. Treatment of Cd14−/− with the BLT1 antagonist blocked 
these effects, confirming that the anti-inflammatory effects of 
this eicosanoid were mediated by BLT1 receptor. Notably, despite 
the higher concentration of LTB4 in the lungs of Cd14−/− animals, 
TsV inoculation did not enhance the recruitment of neutrophils 
to the lungs and MPO activity was similar to vehicle-inoculated 
Cd14−/− animals. LTB4 is widely recognized as a neutrophil 
chemoattractant and activator (50, 51), but our results suggest 
that during TsV-induced inflammation, this lipid mediator does 
not contribute to this phenomenon, instead neutrophils are 
recruited via IL-1β (52). Whether neutrophils from Cd14−/− mice 
express less BLT1 and/or more BLT2 is also an important point. 
However, our results suggest that CD14 signaling may differen-
tially regulate BLT1 expression depending on the leukocyte type. 
Supporting this hypothesis, LPS priming of neutrophils and later 
stimulation with FMLP, C5a, or IL-8 increases their production 
of 5-LO metabolites by a mechanism that depends on CD14 (53). 
However, further investigation is needed to determine if and 
how CD14 regulates differential BLT1/2 expression. Although 
the critical roles of CD14 (54, 55) and IL-1β secretion (3, 56) 
have been investigated during lung inflammation, the results 
presented here demonstrate unrecognized relationships between 
CD14, IL-1β, cAMP, and bioactive lipids.
Recently, CD36 has been described a central coordinator of 
NLRP3 inflammasome activation and IL-1β release during sterile 
inflammation (16). In addition, CD36 mediates phagocytosis of 
apoptotic cells (57, 58) that results in PGE2 release (59). We thus 
hypothesized that CD36 would contribute to the activation of 
NLRP3 and increase IL-1β secretion during scorpion envenoma-
tion. Nevertheless, we found a paradoxical role of this receptor. 
While CD36 mediates inflammatory signaling that results in 
the induction of TNF-α and IL-6, it also specifically regulates 
the release of IL-1β. Indeed, Cd36 deficiency abrogated LTB4 
production, resulting in increased production of PGE2, cAMP, 
and IL-1β by TsV-stimulated macrophages. Furthermore, in vivo 
data confirmed that the inflammatory phenotype of Cd36obl/obl  
mice was due impaired activation of the 5-LO pathway and 
decreased production of LTB4. Inoculation of a lethal dose of TsV 
in Cd36obl/obl mice resulted in robust release of PGE2 and IL-1β, 
with intense lung edema and cell infiltration. Intranasal LTB4 
administration suppressed PGE2 and IL-1β release, blocked lung 
edema, and prevented death in Cd36obl/obl mice, further validating 
an anti-inflammatory function of this eicosanoid. Importantly, 
expression of the CD36 receptor is induced during higher activity 
of 5-LO pathway (60), corroborating a direct relationship between 
CD36 and LTB4 metabolism. CD36 transfected cells exposed to 
different bacteria induce JNK signaling that culminates in IL-8 
and IL-6 production, while NF-κB inhibition does not seem to 
influence this process (61). Interestingly, monocyte-derived mac-
rophages from CD36-deficient humans secrete less TNF-α and 
IL-1β when stimulated with oxidized low-density lipoproteins or 
thrombospondin-1 (62). Previous studies have also shown that 
CD36-deficient bone marrow-derived macrophages or peritoneal 
macrophages produce less IL-1β when incubated with particulate 
ligands (16). Multiple factors may contribute to the opposing 
responses mediated by CD36, such as the nature of the ligands 
(soluble or particulate), the activation/participation other PRRs, 
the presence/absence of cofactors in the microenvironment, such 
as ATP and LPS (16); or even the enhanced CD36 expression 
mediated by activation of 5-LO pathway (60). Although CD36 
induces LTB4 production by mouse macrophages in  vitro, our 
findings show LTB4 is also released through CD36-independent 
mechanism(s) that is, however, unable to contain the TsV-
induced inflammation. Neutrophil is an important LTB4 source 
(63). MPO quantification and lung tissue histology demonstrated 
that Cd36obl/obl mice exhibited a robust neutrophil infiltration in 
the lungs, which can be responsible for LTB4 production after 
envenomation.
In summary, our results demonstrate that CD14 and CD36 are 
important PRRs that sense scorpion venom, but exhibit oppos-
ing functions on the control of IL-1β release and inflammation 
(Figure 7). Upon TsV engagement, CD14 promotes the inflam-
matory response via PGE2/cAMP/IL-1β production, leukocyte 
FigUre 7 | CD14 and CD36 receptors control differential eicosanoid metabolism and inflammation. Tityus serrulatus venom activates the NLRP3 inflammasome  
in macrophages, which requires potassium (K+) efflux, and results in interleukin (IL)-1β release by mouse peritoneal macrophages. This phenomenon is dependent 
on NF-kB activation, which is amplified by PGE2 and repressed by leukotriene (LT)B4 (3). Here, we show that upon TsV recognition, the receptor CD14 upregulates 
the Ptgs2/PGE2/cyclic adenosine monophosphate (cAMP) axis and amplification of IL-1β production and release. By contrast, CD36 shunts eicosanoid metabolism 
toward LTB4 production. This process results in decreased cAMP levels, repressing protein kinase A and NF-kB activation, which reduces IL-1β secretion and 
inflammation. We propose that the balance in eicosanoid metabolism, controlled by CD14 and CD36, regulates the amount of released IL-1β and dictates the 
outcome after scorpion envenomation.
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recruitment, and edema formation, while downregulating the 
5-LO pathway activity and LTB4 release. By contrast, CD36 plays 
a dual role by promoting inflammatory cytokines such as TNF-α 
and IL-6, while repressing IL-1β release. Specifically, it mediates 
LTB4 production, which in turn decreases cAMP production 
to downregulate COX2/PGE2. In consequence, IL-1β levels 
decrease, directly impacting TsV-induced mortality due reduced 
lung inflammation and edema. CD14 and CD36 are potential 
therapeutic targets for several inflammatory diseases. Therefore, 
our findings have strong implications to the full understanding 
of the functions exerted by these receptors, and thus rational for 
drug design. Future investigations will be necessary to confirm 
that the influence of CD14 and CD36 interplay on differential 
eicosanoid metabolism and IL-1β release regulation is not 
restricted to scorpion envenomation.
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